Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16527128 | 0.96 | METAP1 (0.56) | METAP1CYP19A1CYP11B2MPOCYP11B1 | |
| SCHEMBL11471048 | 0.89 | METAP1 (0.59) | METAP1CYP19A1CYP11B2MPOCYP11B1 | |
| SCHEMBL2311211 | 0.86 | METAP1 (0.54) | METAP1CYP19A1CYP11B2ACHEMAPT | |
| SCHEMBL12443519 | 0.82 | METAP1 (0.54) | METAP1CYP19A1CYP11B2ACHEMAPT | |
| SCHEMBL115638 | 0.79 | MAOA (0.58) | METAP1CYP19A1CYP11B2KDM4EHTT | |
| SCHEMBL8321691 | 0.79 | METAP1 (0.56) | METAP1CYP19A1CYP11B2MPOCYP11B1 | |
| SCHEMBL12654036 | 0.79 | CYP19A1 (0.51) | METAP1CYP19A1CYP11B2MPOCYP11B1 | |
| SCHEMBL17108416 | 0.78 | MPO (0.59) | METAP1CYP19A1CYP11B2MPOCYP11B1 | |
| SCHEMBL19278088 | 0.78 | MAOB (0.43) | ESR1ACHE | |
| SCHEMBL31650166 | 0.78 | FFAR4 (0.38) | METAP1CYP19A1CYP11B2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-113999232-B | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-113999232-A | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-108341822-B | FXR receptor modulator and preparation method and application thereof | 广州市恒诺康医药科技有限公司 | 2021-04-16 | — | — | CN | disclosed |
| WO-2020212543-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019228083-A1 | CARBONYL REDUCTASE MUTANT AND USE THEREOF IN REDUCTION OF CYCLOPENTANEDIONE COMPOUND | 中国科学院天津工业生物技术研究所 (CN) | 2019-12-05 | — | — | WO | disclosed |
| WO-2017080966-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-1896391-B1 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | UNIV BAYLOR (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| US-7084154-B2 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA DRUG DISCLOVERY, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA, INC (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004071445-A2 | 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004071445-A2 | 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-4237306-A | ELECTROPHILIC REACTIONS WITH ALKYL ARYL KETONES TO PRODUCE METHYL ARYL ALKANOATES | EMERY INDUSTRIES, INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4172955-A | REARRANGMENT OF A CINNAMALDEHYDE TO A PHENYLMALONDIALDEHYDE TETRAMETHYL DISACETAL | EMERY INDUSTRIES, INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4067823-A | Thallium(III) reagents supported on montmorillonite clay minerals and oxythallation processes for utilizing same | EMERY INDUSTRIES, INC. (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | TUBB, TUBB3, TUBB1 | METAP1 523/4885CYP19A1 4590/4885CYP11B2 3816/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | METAP1 3160/4885CYP19A1 146/4885CYP11B2 1251/4885 |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | OPRL1, OPRM1, OPRK1 | METAP1 504/4885CYP19A1 1385/4885CYP11B2 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.